Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pyrilinks cleared for US:

This article was originally published in Clinica

Executive Summary

Metra Biosystems' (US) Pyrilinks bone resorption tests have been cleared for US marketing by the FDA. The two urine-based assays (polyclonal and monoclonal) provide a quantitative measure of the excretion of pyridinium crosslinks as an indicator of type I collagen resorption. These assays join Alkphase-B, which measures serum levels of alkaline phosphatase, cleared in the US in August. Pyrilinks-D, which measures deoxypyridinoline, is pending FDA clearance.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel